U.S. HIV/AIDS Therapies Markets

 

Regular Price: USD 2,450

Special Price USD 1,715

30% OFF

* Required Fields

Regular Price: USD 2,450

Special Price USD 1,715

PAY BY INVOICE

Be the first to review this product

The U.S. HIV/AIDS Therapies Markets report covers the various antiretroviral (ARV) drugs that are currently available in the U.S. namely, NRTIs, PIs and NNRTIs. The report also covers the pipeline drugs from the existing and novel ARV categories, and the HIV vaccines pipeline. Frost & Sullivan Market Engineering Analysis, major market/technology trends, challenges, drivers and restraints and forecasts are covered on a total level and also as at the levels of the various segments. The report cites three prestigious Frost & Sullivan Market Engineering Awards to active industry participants for effective industry approaches.

Table of Contents

U.S. HIV/AIDS Therapies Markets, Executive SummaryExecutive SummaryExecutive SummaryU.S. HIV/AIDS Therapies Markets, IntroductionHIV/AIDS: Definition and ClassificationReport ScopeThe Human Immunodeficiency VirusAcquired Immuno-Deficiency Syndrome(AIDS)Etiology and DemographyDiagnostic TestsOverview of HIV/AIDS Therapies Highly Active Antiretroviral Therapy(HAART)Challenges and StrategiesOverview of ChallengesChallenge 1: Higher Drug ResistanceChallenge 2: Inconsistent Patient AdherenceChallenge 3: Higher Pill BurdensChallenge 4: Drug-Induced DyslipidemiaChallenge 5: Patients' Lower TolerabilityChallenge 6: Limited Funds and High Drug PricesMarket DynamicsMarket DriversMarket RestraintsPricing TrendsDemand AnalysisRevenue ForecastsMarket Engineering AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Engineering AwardsMarketing Strategy Leadership AwardProduct Innovation AwardBusiness Development Strategy AwardU.S. HIV/AIDS Therapies Markets, Nucleoside Reverse Transcriptase Inhibitors MarketMarket OverviewIntroductionProduct Analysis - Existing NRTIsProduct Analysis - Pipeline NRTIsMarket DriversMarket RestraintsMarket DynamicsPricing AnalysisRevenue ForecastsMarket Engineering AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisU.S. HIV/AIDS Therapies Markets, Protease Inhibitors MarketMarket OverviewIntroductionProduct Analysis - Existing Protease InhibitorsProduct Analysis - Pipeline Protease InhibitorsMarket DriversMarket RestraintsMarket DynamicsPricing AnalysisRevenue ForecastsMarket Engineering AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisU.S. HIV/AIDS Therapies Markets, Non-Nucleoside Reverse Transcriptase Inhibitors MarketMarket OverviewIntroductionProduct Analysis - Existing NNRTIsProduct Analysis - Pipeline NNRTIsMarket DriversMarket RestraintsMarket DynamicsPricing AnalysisRevenue ForecastsMarket Engineering AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisU.S. HIV/AIDS Therapies Markets, Future HIV/AIDS TherapiesPipeline ARV Drugs in Novel CategoriesHIV Entry InhibitorsImmune-Based TherapiesMiscellaneous Antiretroviral TherapiesMarket Share AnalysisHIV/AIDS VaccinesOverviewVaccines in Phase III StageOther Pipeline Vaccines




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.